Block copolymer micelles for controlled delivery of glycolytic enzyme inhibitors

Pharmaceutical Research

Volumn 29, Issue 3, 2012, Pages 847-855

  Akter, Shanjida ^a   Clem, Brian F ^b   Lee, Hyun Jin ^a   Chesney, Jason ^b   Bae, Younsoo ^a  

^a University of Kentucky   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

Cancer; Drug delivery; Fructose 2,6 bisphosphate; Glycolysis; Polymer micelles

Indexed keywords

3 (3 PYRIDINYL) 1 (4 PYRIDINYL) 2 PROPEN 1 ONE; COPOLYMER; ENZYME INHIBITOR; UNCLASSIFIED DRUG; 3-(3-PYRIDINYL)-1-(4-PYRIDINYL)-2-PROPEN-1-ONE; 6 PHOSPHOFRUCTO 2 KINASE; ANTINEOPLASTIC AGENT; MACROGOL DERIVATIVE; NANOCONJUGATE; POLY(ETHYLENE GLYCOL) POLY(ASPARTATE HYDRAZIDE); POLY(ETHYLENE GLYCOL)-POLY(ASPARTATE HYDRAZIDE); PROTEIN; PYRIDINE DERIVATIVE;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED DRUG RELEASE; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; FREEZE DRYING; HELA CELL; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LEUKEMIA CELL LINE; LEWIS CARCINOMA; MICELLE; MOUSE; NONHUMAN; PARTICLE SIZE; PH; PRIORITY JOURNAL; ANIMAL; CELL SURVIVAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GLYCOLYSIS; NEOPLASM; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DELAYED-ACTION PREPARATIONS; ENZYME INHIBITORS; GLYCOLYSIS; HUMANS; MICE; MICELLES; NANOCONJUGATES; NEOPLASMS; PHOSPHOFRUCTOKINASE-2; POLYETHYLENE GLYCOLS; PROTEINS; PYRIDINES;

EID: 84862335729     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0613-4     Document Type: Article

References (34)

1. Berdanier CD. Drugs, nutrients, and hormones in mitochondrial function. Oxid Stress Dis. 2005;16:455-506.
2. Vizan P, Boros LG, Figueras A, Capella G, Mangues R, Bassilian S, et al. K-ras codon-specific mutations produce distinctive metabolic phenotypes in human fibroblasts. Cancer Res. 2005;65:5512-5.
3. Hue L, Rousseau GG. Fructose-2,6-bisphosphate and the control of glycolysis by growth-factors, tumor promoters and oncogenes. Adv Enzyme Regul. 1993;33:97-110.
4. Ramanathan A, Wang C, Schreiber SL. Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc Natl Acad Sci. 2005;102:5992-7.
5. Mazurek S, Zwerschke W, Jansen-Durr P, Eigenbrodt E. Metabolic cooperation between different oncogenes during cell transformation: interaction between activated ras and hpv-16 e7. Oncogene. 2001;20:6891-8.
6. Telang S, Yalcin A, Clem AL, Bucala R, Lane AN, Eaton JW, et al. Ras transformation requires metabolic control by 6- phosphofructo-2-kinase. Oncogene. 2006;25:7225-34.
7. Clem B, Telang S, Clem A, Yalcin A, Meier J, Simmons A, et al. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Mol Cancer Ther. 2008;7:110-20.
8. Cukierman E, Khan DR. The benefits and challenges associated with the use of drug delivery systems in cancer therapy. Biochem Pharmacol. 2010;80:762-70.
9. Matsumura Y, Kataoka K. Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci. 2009;100:572-9.
10. Kataoka K, Kwon GS, Yokoyama M, Okano T, Sakurai Y. Block-copolymer micelles as vehicles for drug delivery. J Control Release. 1993;24:119-32.
11. Kwon GS, Yokoyama M, Okano T, Sakurai Y, Kataoka K. Biodistribution of micelle-forming polymer-drug conjugates. Pharm Res. 1993;10:970-4.
12. Kwon GS, Naito M, Kataoka K, Yokoyama M, Sakurai Y, Okano T. Block copolymer micelles as vehicles for hydrophobic drugs. Colloids Surf B Biointerfaces. 1994;2:429-34.
13. Matsumura Y. Poly (amino acid) micelle nanocarriers in preclinical and clinical studies. Adv Drug Deliv Rev. 2008;60:899-914.
14. Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev. 2001;47:113-31.
15. Yokoyama M, Kwon GS, Okano T, Sakurai Y, Naito M, Kataoka K. Influencing factors on in-vitro micelle stability ofadriamycin-block copolymer conjugates. J Control Release. 1994;28:59-65.
16. Gao ZS, Eisenberg A. A model of micellization for block-copolymers in solutions. Macromolecules. 1993;26:7353-60.
17. Allen C, Maysinger D, Eisenberg A. Nano-engineering block copolymer aggregates for drug delivery. Colloid Surf B. 1999;16:3-27.
18. West KR, Otto S. Reversible covalent chemistry in drug delivery. Curr Drug Discov Technol. 2005;2:123-60.
19. Cammas S, Kataoka K. Functional poly[(ethylene oxide)-co- (beta-benzyl-l-aspartate)] polymeric micelles - block-copolymer synthesis and micelles formation. Macromol Chem Phys. 1995;196:1899-905.
20. Lavasanifar A, Samuel J, Kwon GS. Poly(ethylene oxide)-blockpoly(l-amino acid) micelles for drug delivery. Adv Drug Deliv Rev. 2002;54:169-90.
21. Lee HJ, Ponta A, Bae Y. Polymer nanoassemblies for cancer treatment and imaging. Ther Deliv. 2010;1:803-17.
22. Bae Y, Jang WD, Nishiyama N, Fukushima S, Kataoka K. Multifunctional polymeric micelles with folate-mediated cancer cell targeting and ph-triggered drug releasing properties for active intracellular drug delivery. Mol Biosyst. 2005;1:242-50.
23. Bae Y, Kataoka K. Intelligent polymeric micelles from functional poly(ethylene glycol)-poly(amino acid) block copolymers. Adv Drug Deliv Rev. 2009;61:768-84.
24. Jones AT, Gumbleton M, Duncan R. Understanding endocytic pathways and intracellular trafficking: a prerequisite for effective design of advanced drug delivery systems. Adv Drug Deliv Rev. 2003;55:1353-7.
25. Vander Heiden MG, Thompson CB, Cantley LC. Understanding the warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029-33.
26. Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med. 2008;49:24s-42s.
27. Yokoyama M, Kwon GS, Okano T, Sakurai Y, Seto T, Kataoka K. Preparation of micelle-forming polymer-drug conjugates. Bioconjugate Chem. 1992;3:295-301.
28. Ponta A, Bae Y. Peg-poly(amino acid) block copolymer micelles for tunable drug release. Pharm Res. 2010;27:2330-42.
29. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev. 1997;26:71-90.
30. Wexler EJ, Gravallese EM, Czerniak PM, Devenny JJ, Longtine J, Wong MK, et al. Tumor biology: use of tiled images in conjunction with measurements of cellular proliferation and death in response to drug treatments. Clin Cancer Res. 2000;6:3361-70.
31. Bae Y, Nishiyama N, Fukushima S, Koyama H, Matsumura Y, Kataoka K. Preparation and biological characterization of polymeric micelle drug carriers with intracellular ph-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. Bioconjugate Chem. 2005;16:122-30.
32. Kataoka K, Matsumoto T, Yokoyama M, Okano T, Sakurai Y, Fukushima S, et al. Doxorubicin-loaded poly(ethylene glycol)-poly (beta-benzyl-l-aspartate) copolymer micelles: their pharmaceutical characteristics and biological significance. J Control Release. 2000;64:143-53.
33. Suzuki H, Nakai D, Seita T, Sugiyama Y. Design of a drug delivery system for targeting based on pharmacokinetic consideration. Adv Drug Deliv Rev. 1996;19:335-57.
34. Takakura Y, Hashida M. Macromolecular carrier systems for targeted drug delivery: pharmacokinetic considerations on biodistribution. Pharm Res. 1996;13:820-31.